Pcas: 2020 Net Sales
Ecully, January 28, 2021
2020 NET SALES
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of December 31, 2020.
PCAS Group consolidated net sales amounted to
€194.1 million as of December 31, 2020, a decrease of 3.4%
compared to the same period in the previous financial year (-2.7%
at constant exchange rate).
|
In millions of euros |
|
2020 |
|
2019 |
|
% change |
|
2020
At a constant exchange rate |
|
% change |
| |
|
|
|
|
|
|
|
|
|
|
|
Net sales as of 31 december |
|
194,1 |
|
200,9 |
|
-3,4% |
|
195,4 |
|
-2,7% |
|
Pharmaceutical Synthesis |
|
135,2 |
|
127,7 |
|
5,9% |
|
136,0 |
|
6,6% |
|
Fine Specialty Chemicals |
|
58,9 |
|
73,2 |
|
-19,6% |
|
59,3 |
|
-19,0% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business in Health
generated sales of €135.2 million, up 5.9% compared to 2019 (+6.6%
at constant exchange rate). This growth can mainly be attributed to
two effects: (i) a greater operational performance at one of our
sites in the Greater Paris region and (ii) the mobilization of
PCAS’ Pharmaceutical Synthesis business to respond to the health
emergency in the context of Covid-19, in particular through the
production of hydroalcoholic solution marketed under the Naaha
brand, created for this purpose.
Fine Specialty Chemicals
Net sales of fine specialty chemicals amounted
to €58.9 million, down 19.6% compared to 2019 (-19.0% at constant
exchange rate). The Electronics business showed resilience during
the crisis. However, the Lubricants and Fine Chemicals businesses
both experienced a sharp decrease, in particular the Lubricants
business which was hit very hard by the health crisis, with a
slight rebound at the end of the year.
Outlook
As mentioned in our previous press releases
since late March 2020, the global health crisis relating to the
Covid-19 is changing by the day, and there is still a lot of
uncertainties regarding its duration, its extent and its effects on
companies' production lines and consumption in general.
The PCAS Group has not seen any significant
impact on its business activities and earnings to date except for
the sharp decline in demand for Lubricants and the delayed
commissioning of the new production unit in
Villeneuve-la-Garenne.
Consequently, the PCAS Group’s current operating
income and net income will remain substantially negative in 2020.
The annual financial statements are currently being prepared. The
financial statements will be approved by the Board of Directors and
published on February 25, 2021.
In any event, it is still hard to anticipate the
potential impacts in the medium term. This crisis calls for
cautious measures. Due to the exceptional circumstances, the Group
has suspended its financial targets and its strategic business
objectives until the situation becomes clearer.
NEXT FINANCIAL DISCLOSURE:
Results at December 31, 2020, on February 25,
2021
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €194.1 million in 2020 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
|
PCAS |
Newcap |
|
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor |
|
Tél. : +33 1 69 79 60 00pcas@newcap.eu |
Tél. : +33 1 44 71 98 53pcas@newcap.eu |
- PCAS - Communique de presse - Chiffre d'affaires
2020_en-US
Grafico Azioni PCAS (EU:PCA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni PCAS (EU:PCA)
Storico
Da Apr 2023 a Apr 2024
